Works by Beijnen, Jos H

Results: 375

EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid.

Published in:

Journal of Neuro-Oncology, 2018, v. 137, n. 1, p. 1, doi. 10.1007/s11060-017-2691-6

By:

van Bussel, Mark T. J.;
Pluim, Dick;
Bol, Mijke;
Beijnen, Jos H.;
Schellens, Jan H. M.;
Brandsma, Dieta

Publication type:

Article

Fixed Dosing of Monoclonal Antibodies in Oncology.

Published in:

Oncologist, 2017, v. 22, n. 10, p. 1212, doi. 10.1634/theoncologist.2017-0167

By:

Hendrikx, Jeroen J.M.A.;
Haanen, John B.A.G.;
Voest, Emile E.;
Schellens, Jan H.M.;
Huitema, Alwin D.R.;
Beijnen, Jos H.

Publication type:

Article

BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies.

Published in:

Oncologist, 2017, v. 22, n. 7, p. 864, doi. 10.1634/theoncologist.2017-0031

By:

van Brummelen, Emilie M. J.;
de Boer, Anthonius;
Beijnen, Jos H.;
Schellens, Jan H. M.

Publication type:

Article

Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.

Published in:

Oncologist, 2016, v. 21, n. 10, p. 1260, doi. 10.1634/theoncologist.2016-0061

By:

Brummelen, Emilie M.J.;
Ros, Willeke;
Wolbink, Gertjan;
Beijnen, Jos H.;
Schellens, Jan H.M.

Publication type:

Article

A Phase 1 Dose‐Escalation Study of Low‐Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 6, p. 607, doi. 10.1002/cpdd.880

By:

Weger, Vincent A.;
Vermunt, Marit A.C.;
Stuurman, Frederik E.;
Burylo, Artur M.;
Damoiseaux, David;
Hendrikx, Jeroen J.M.A.;
Sawicki, Emilia;
Moes, Johannes J.;
Huitema, Alwin D.R.;
Nuijen, Bastiaan;
Rosing, Hilde;
Mergui‐Roelvink, Marja;
Beijnen, Jos H.;
Marchetti, Serena

Publication type:

Article

Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 5, p. 552, doi. 10.1002/cpdd.840

By:

Roosendaal, Jeroen;
Rosing, Hilde;
Beijnen, Jos H.

Publication type:

Article

ATP-binding cassette transporter inhibitor potency and substrate drug affinity are critical determinants of successful drug delivery enhancement to the brain.

Published in:

Fluids & Barriers of the CNS, 2024, v. 21, n. 1, p. 1, doi. 10.1186/s12987-024-00562-4

By:

Lentzas, Aristeidis;
de Gooijer, Mark C.;
Zuidema, Stefanie;
Meurs, Amber;
Çitirikkaya, Ceren H.;
Venekamp, Nikkie;
Beijnen, Jos H.;
van Tellingen, Olaf

Publication type:

Article

Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.

Published in:

Pigment Cell & Melanoma Research, 2015, v. 28, n. 3, p. 307, doi. 10.1111/pcmr.12364

By:

Vogel, Celia J.;
Smit, Marjon A.;
Maddalo, Gianluca;
Possik, Patricia A.;
Sparidans, Rolf W.;
Burg, Sjoerd H.;
Verdegaal, Els M.;
Heck, Albert J. R.;
Samatar, Ahmed A.;
Beijnen, Jos H.;
Altelaar, A. F. Maarten;
Peeper, Daniel S.

Publication type:

Article

Drug-Drug Interaction between Itraconazole and the Antiretroviral Drug Lopinavir/Ritonavir in an HIV-1--Infected Patient with Disseminated Histoplasmosis.

Published in:

Clinical Infectious Diseases, 2004, v. 38, n. 8, p. e73, doi. 10.1086/382675

By:

Crommentuyn, Kristel M. L.;
Mulder, Jan W.;
Sparidans, Rolt W.;
Huitema, Alwin D. R.;
Schellens, Jan H. M.;
Beijnen, Jos H.

Publication type:

Article

Sensitive liquid chromatography/tandem mass spectrometry assay for absolute quantification of ITIH<sub>4</sub>-derived putative biomarker peptides in clinical serum samples.

Published in:

Rapid Communications in Mass Spectrometry: RCM, 2010, v. 24, n. 13, p. 1842, doi. 10.1002/rcm.4588

By:

van den Broek, Irene;
Sparidans, Rolf W.;
Schellens, Jan H. M.;
Beijnen, Jos. H.

Publication type:

Article

Simultaneous quantification of 2′,2′-difluorodeoxycytidine and 2′,2′-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry.

Published in:

Rapid Communications in Mass Spectrometry: RCM, 2009, v. 23, n. 19, p. 3040, doi. 10.1002/rcm.4212

By:

Jansen, Robert S.;
Rosing, Hilde;
Schellens, Jan H. M.;
Beijnen, Jos H.

Publication type:

Article

Validated assay for the simultaneous quantification of total vincristine and actinomycin-D concentrations in human EDTA plasma and of vincristine concentrations in human plasma ultrafiltrate by high-performance liquid chromatography coupled with tandem mass spectrometry

Published in:

Rapid Communications in Mass Spectrometry: RCM, 2009, v. 23, n. 6, p. 763, doi. 10.1002/rcm.3938

By:

Damen, Carola W. N.;
Israëls, Trijn;
Caron, Huib N.;
Schellens, Jan H.M.;
Rosing, Hilde;
Beijnen, Jos H.

Publication type:

Article

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.

Published in:

2020

By:

van Geel, Robin M. J. M.;
van Brummelen, Emilie M. J.;
Eskens, Ferry A. L. M.;
Huijberts, Sanne C. F. A.;
de Vos, Filip Y. F. L.;
Lolkema, Martijn P. J. K.;
Devriese, Lot A.;
Opdam, Frans L.;
Marchetti, Serena;
Steeghs, Neeltje;
Monkhorst, Kim;
Thijssen, Bas;
Rosing, Hilde;
Huitema, Alwin D. R.;
Beijnen, Jos H.;
Bernards, René;
Schellens, Jan H. M.

Publication type:

journal article

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.

Published in:

2017

By:

Meulendijks, Didier;
Henricks, Linda M;
Jacobs, Bart A W;
Aliev, Abidin;
Deenen, Maarten J;
de Vries, Niels;
Rosing, Hilde;
van Werkhoven, Erik;
de Boer, Anthonius;
Beijnen, Jos H;
Mandigers, Caroline M P W;
Soesan, Marcel;
Cats, Annemieke;
Schellens, Jan H M

Publication type:

journal article

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.

Published in:

British Journal of Cancer, 2015, v. 113, n. 3, p. 396, doi. 10.1038/bjc.2015.256

By:

van der Noll, Ruud;
Marchetti, Serena;
Steeghs, Neeltje;
Beijnen, Jos H;
Mergui-Roelvink, Marja W J;
Harms, Emmy;
Rehorst, Harriet;
Sonke, Gabe S;
Schellens, Jan H M

Publication type:

Article

Presence of Five Chemotherapeutic Drugs in Breast Milk as a Guide for the Safe Use of Chemotherapy During Breastfeeding: Results From a Case Series.

Published in:

Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 2, p. 404, doi. 10.1002/cpt.2626

By:

Damoiseaux, David;
Calpe, Silvia;
Rosing, Hilde;
Beijnen, Jos H.;
Huitema, Alwin D. R.;
Lok, Christianne;
Dorlo, Thomas P. C.;
Amant, Frédéric

Publication type:

Article

Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.

Published in:

Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 1, p. 62, doi. 10.1002/cpt.2608

By:

de With, Mirjam;
Knikman, Jonathan;
de Man, Femke M.;
Lunenburg, Carin A. T. C.;
Henricks, Linda M.;
van Kuilenburg, André B. P.;
Maring, Jan G.;
van Staveren, Maurice C.;
de Vries, Niels;
Rosing, Hilde;
Beijnen, Jos H.;
Pluim, Dick;
Modak, Anil;
Imholz, Alex L. T.;
van Schaik, Ron H. N.;
Schellens, Jan H. M.;
Gelderblom, Hans;
Cats, Annemieke;
Guchelaar, Henk‐Jan;
Mathijssen, Ron H. J.

Publication type:

Article

Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer.

Published in:

Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 2, p. 477, doi. 10.1002/cpt.2455

By:

Molenaar‐Kuijsten, Laura;
Braal, C. Louwrens;
Groenland, Stefanie L.;
de Vries, Niels;
Rosing, Hilde;
Beijnen, Jos H.;
Koolen, Stijn L.W.;
Vulink, Annelie J.E.;
van Dongen, Marloes G.J.;
Mathijssen, Ron H.J.;
Huitema, Alwin D.R.;
Steeghs, Neeltje

Publication type:

Article

Response to "Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence".

Published in:

Clinical Pharmacology & Therapeutics, 2021, v. 110, n. 5, p. 1164, doi. 10.1002/cpt.2372

By:

Groenland, Stefanie L.;
Geel, Dieuwertje R.;
Beijnen, Jos H.;
Smit, Egbert F.;
Huitema, Alwin D. R.;
Steeghs, Neeltje

Publication type:

Article

Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?

Published in:

Clinical Pharmacology & Therapeutics, 2021, v. 109, n. 3, p. 591, doi. 10.1002/cpt.2069

By:

Knikman, Jonathan E.;
Gelderblom, Hans;
Beijnen, Jos H.;
Cats, Annemieke;
Guchelaar, Henk‐Jan;
Henricks, Linda M.

Publication type:

Article

Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients.

Published in:

Clinical Pharmacology & Therapeutics, 2021, v. 109, n. 2, p. 394, doi. 10.1002/cpt.1989

By:

Groenland, Stefanie L.;
Geel, Dieuwertje R.;
Janssen, Julie M.;
Vries, Niels;
Rosing, Hilde;
Beijnen, Jos H.;
Burgers, Jacobus A.;
Smit, Egbert F.;
Huitema, Alwin D.R.;
Steeghs, Neeltje

Publication type:

Article

Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology.

Published in:

Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 3, p. 494, doi. 10.1002/cpt.1808

By:

Janssen, Julie M.;
Dorlo, Thomas P. C.;
Steeghs, Neeltje;
Beijnen, Jos H.;
Hanff, Lidwien M.;
Eijkelenburg, Natasha K. A.;
Lugt, Jasper;
Zwaan, C. Michel;
Huitema, Alwin D. R.

Publication type:

Article

Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and <sup>11</sup>C-Erlotinib PET.

Published in:

Journal of Nuclear Medicine, 2018, v. 59, n. 6, p. 973, doi. 10.2967/jnumed.117.195800

By:

Verheijen, Remy B.;
Yaqub, Maqsood;
Sawicki, Emilia;
van Tellingen, Olaf;
Lammertsma, Adriaan A.;
Nuijen, Bastiaan;
Schellens, Jan H. M.;
Beijnen, Jos H.;
Huitema, Alwin D. R.;
Hendrikse, N. Harry;
Steeghs, Neeltje

Publication type:

Article

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.

Published in:

2017

By:

van der Hiel, Bernies;
Haanen, John B. A. G.;
Stokkel, Marcel P. M.;
Peeper, Daniel S.;
Jimenez, Connie R.;
Beijnen, Jos H.;
van de Wiel, Bart A.;
Boellaard, Ronald;
van den Eertwegh, Alfons J. M.;
REPOSIT study group

Publication type:

journal article

Exposure‐Response Assessment of Enzalutamide and Its Major Metabolites in a Real‐World Cohort of Patients with Metastatic Castration‐Resistant Prostate Cancer.

Published in:

Pharmacotherapy, 2019, v. 39, n. 12, p. 1137, doi. 10.1002/phar.2339

By:

Nuland, Merel;
Bergman, Andries M.;
Rosing, Hilde;
Vries, Niels;
Huitema, Alwin D.R.;
Beijnen, Jos H.

Publication type:

Article

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand–foot syndrome.

Published in:

European Journal of Clinical Pharmacology, 2013, v. 69, n. 12, p. 2065, doi. 10.1007/s00228-013-1579-4

By:

Lankheet, Nienke A. G.;
Huitema, Alwin D. R.;
Mallo, Henk;
Adriaansz, Sandra;
Haanen, John B. A. G.;
Schellens, Jan H. M.;
Beijnen, Jos H.;
Blank, Christian U.

Publication type:

Article

Screening for polymorphisms in the PXR gene in a Dutch population.

Published in:

European Journal of Clinical Pharmacology, 2006, v. 62, n. 5, p. 395, doi. 10.1007/s00228-006-0108-0

By:

Bosch, Tessa M.;
Deenen, Maarten;
Pruntel, Roelof;
Smits, Paul H. M.;
Schellens, Jan H. M.;
Beijnen, Jos H.;
Meijerman, Irma

Publication type:

Article

Incidence and risk factors for nevirapine-associated rash.

Published in:

European Journal of Clinical Pharmacology, 2003, v. 59, n. 5/6, p. 457, doi. 10.1007/s00228-003-0613-3

By:

de Maat, Monique M. R.;
ter Heine, Rob;
Mulder, Jan W.;
Meenhorst, Pieter L.;
Mairuhu, Albert T. A.;
van Gorp, Eric C. M.;
Huitema, Alwin D. R.;
Beijnen, Jos H.

Publication type:

Article

A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure–response relationships: a proof-of-concept study with alectinib.

Published in:

Cancer Chemotherapy & Pharmacology, 2024, v. 94, n. 3, p. 453, doi. 10.1007/s00280-024-04698-w

By:

Lin, Lishi;
van der Noort, Vincent;
Steeghs, Neeltje;
Ruiter, Gerrina;
Beijnen, Jos H.;
Huitema, Alwin D. R.

Publication type:

Article

Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment.

Published in:

Cancer Chemotherapy & Pharmacology, 2024, v. 94, n. 1, p. 79, doi. 10.1007/s00280-024-04662-8

By:

Loos, Nancy H.C.;
Bui, Viët;
de Jong, Daniëlle H.;
Lebre, Maria C.;
Rosing, Hilde;
Beijnen, Jos H.;
Schinkel, Alfred H.

Publication type:

Article

Are novel oral oncolytics underdosed in obese patients?

Published in:

Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 2, p. 129, doi. 10.1007/s00280-023-04601-z

By:

Lin, Lishi;
van der Meer, Ellen K. O.;
Steeghs, Neeltje;
Beijnen, Jos H.;
Huitema, Alwin D. R.

Publication type:

Article

Assay performance and stability of uracil and dihydrouracil in clinical practice.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 3, p. 257, doi. 10.1007/s00280-023-04518-7

By:

Knikman, Jonathan E.;
Rosing, Hilde;
Guchelaar, Henk-Jan;
Cats, Annemieke;
Beijnen, Jos H.

Publication type:

Article

Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies.

Published in:

2022

By:

van Eijk, Maarten;
Yu, Huixin;
Sawicki, Emilia;
de Weger, Vincent A.;
Nuijen, Bastiaan;
Dorlo, Thomas P. C.;
Beijnen, Jos H.;
Huitema, Alwin D. R.

Publication type:

journal article

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.

Published in:

Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 6, p. 785, doi. 10.1007/s00280-022-04433-3

By:

Vermunt, Marit A. C.;
van Nuland, Merel;
van der Heijden, Lisa T.;
Rosing, Hilde;
Beijnen, Jos. H.;
Bergman, Andries M.

Publication type:

Article

Is age just a number? A population pharmacokinetic study of gemcitabine.

Published in:

Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 5, p. 697, doi. 10.1007/s00280-022-04431-5

By:

Boosman, René J.;
Crombag, Marie-Rose B. S.;
van Erp, Nielka P.;
Beijnen, Jos H.;
Steeghs, Neeltje;
Huitema, Alwin D. R.

Publication type:

Article

Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours.

Published in:

2021

By:

Vermunt, Marit A. C.;
van der Heijden, Lisa T.;
Hendrikx, Jeroen J. M. A.;
Schinkel, Alfred H.;
de Weger, Vincent A.;
van der Putten, Eric;
van Triest, Baukelien;
Bergman, Andries M.;
Beijnen, Jos H.

Publication type:

journal article

Processing of Doxorubicin-Containing Liposomes by Liver Macrophages in Vitro.

Published in:

Journal of Liposome Research, 1989, v. 1, n. 2, p. 195, doi. 10.3109/08982108909035991

By:

Storm, Gert;
Regts, Joke;
Beijnen, Jos H.;
Roerdink, Frits H.

Publication type:

Article

Automated synthesis and quality control of [99mTc]Tc-PSMA for radioguided surgery (in a [68Ga]Ga-PSMA workflow).

Published in:

EJNMMI Radiopharmacy & Chemistry, 2020, v. 5, n. 1, p. 1, doi. 10.1186/s41181-020-00095-9

By:

Aalbersberg, Else A.;
van Andel, Lotte;
Geluk-Jonker, Martine M.;
Beijnen, Jos H.;
Stokkel, Marcel P. M.;
Hendrikx, Jeroen J. M. A.

Publication type:

Article

Concise Drug Review: Azacitidine and Decitabine.

Published in:

Oncologist, 2013, v. 18, n. 5, p. 618, doi. 10.1634/theoncologist.2012-0465

By:

DERISSEN, ELLEN J. B.;
BEIJNEN, JOS H.;
SCHELLENS, JAN H. M.

Publication type:

Article

Concise Drug Review: Pazopanib and Axitinib.

Published in:

Oncologist, 2012, v. 17, n. 8, p. 1081, doi. 10.1634/theoncologist.2012-0055

By:

Van Geel, Robin M. J. M.;
Beijnen, Jos H.;
Schellens, Jan H. M.

Publication type:

Article

Letter to the Editor Regarding 'A Prospective, Controlled Study of the Botanical Compound Mixture LCS101 for Chemotherapy-Induced Hematological Complications in Breast Cancer' by Yaal-Hahoshen et al. (The Oncologist 2011;16:1197-1202)

Published in:

2012

By:

Mooiman, Kim D.;
K. L. Goey, Andrew;
Meijerman, Irma;
Beijnen, Jos H.;
H.M. Schellens, Jan

Publication type:

Journal Article

Letter to the Editor Regarding "A Prospective, Controlled Study of the Botanical Compound Mixture LCS101 for Chemotherapy-Induced Hematological Complications in Breast Cancer" by Yaal-Hahoshen et al. (The Oncologist 2011;16:1197-1202).

Published in:

2012

By:

MOOIMAN, KIM D.;
K. L. GOEY, ANDREW;
MEIJERMAN, IRMA;
BEIJNEN, JOS H.;
H.M. SCHELLENS, JAN

Publication type:

Letter

Lapatinib for Advanced or Metastatic Breast Cancer.

Published in:

Oncologist, 2012, v. 17, n. 4, p. 536, doi. 10.1634/theoncologist.2011-0461

By:

OPDAM, FRANS L.;
GUCHELAAR, HENK-JAN;
BEIJNEN, JOS H.;
SCHELLENS, JAN H. M.

Publication type:

Article

Clinical Pharmacology: Pharmacogenetics: Opportunities for Patient-Tailored Anticancer Therapy Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects.

Published in:

Oncologist, 2011, v. 16, n. 7, p. 1006, doi. 10.1634/theoncologist.2010-0261

By:

DEENEN, MAARTEN J.;
CATS, ANNEMIEKE;
BEIJNEN, JOS H.;
SCHELLENS, JAN H. M.

Publication type:

Article

Clinical Pharmacology: Pharmacogenetics: Opportunities for Patient-Tailored Anticancer Therapy Part 3: Pharmacogenetic Variability in Phase II Anticancer Drug Metabolism.

Published in:

Oncologist, 2011, v. 16, n. 7, p. 992, doi. 10.1634/theoncologist.2010-0260

By:

DEENEN, MAARTEN J.;
CATS, ANNEMIEKE;
BEIJNEN, JOS H.;
SCHELLENS, JAN H. M.

Publication type:

Article

Clinical Pharmacology: Pharmacogenetics: Opportunities for Patient-Tailored Anticancer Therapy Part 2: Pharmacogenetic Variability in Drug Transport and Phase I Anticancer Drug Metabolism.

Published in:

Oncologist, 2011, v. 16, n. 6, p. 820, doi. 10.1634/theoncologist.2010-0259

By:

Deenen, Maarten J.;
Cats, Annemieke;
Beijnen, Jos H.;
Schellens, Jan H. M.

Publication type:

Article

Clinical Pharmacology: Pharmacogenetics: Opportunities for Patient-Tailored Anticancer Therapy Part 1: Background, Methodology, and Clinical Adoption of Pharmacogenetics.

Published in:

Oncologist, 2011, v. 16, n. 6, p. 811, doi. 10.1634/theoncologist.2010-0258

By:

Deenen, Maarten J.;
Cats, Annemieke;
Beijnen, Jos H.;
Schellens, Jan H. M.

Publication type:

Article

Trastuzumab.

Published in:

Oncologist, 2011, v. 16, n. 6, p. 800, doi. 10.1634/theoncologist.2010-0035

By:

Boekhout, Annelies H.;
Beijnen, Jos H.;
Schellens, Jan H. M.

Publication type:

Article

Inhibitors of mTOR.

Published in:

Oncologist, 2010, v. 15, n. 12, p. 1262, doi. 10.1634/theoncologist.2010-0196

By:

KLÜMPEN, HEINZ-JOSEF;
BEIJNEN, JOS H.;
GURNEY, HOWARD;
SCHELLENS, JAN H. M.

Publication type:

Article

Bevacizumab.

Published in:

Oncologist, 2010, v. 15, n. 8, p. 819, doi. 10.1634/theoncologist.2009-0317

By:

KAZAZI-HYSENI, FILIS;
BEIJNEN, JOS H.;
SCHELLENS, JAN H. M.

Publication type:

Article